London, Jan 21, 2026, 09:23 GMT — Regular session
Shares of Haleon PLC (HLN.L) ticked up 1.4% to 378.2 pence by 0924 GMT Wednesday, following a close at 372.9 pence the day before. The stock swung between 376.9 and 384.1 pence during early trading. 1
This shift is significant as Haleon approaches its upcoming full-year results, leaving scant new company updates before then. That usually means broker notes and routine investor materials carry more influence than during quieter periods.
It also shifts attention to the swing factors that can turn sentiment in consumer health: demand for winter cough-and-cold products, currency translation effects, and how much pricing holds once volumes stabilize.
Jefferies boosted its price target for Haleon to 450 pence from 440 pence, maintaining a buy rating following updated forecasts ahead of the fiscal-year results. 2
On Tuesday, Haleon released a pre-announcement “aide memoire” that pulls together statements from previous updates, clarifying these reflect their original dates and aren’t profit forecasts. The company stuck to its full-year 2025 guidance of around 3.5% organic revenue growth—excluding currency and deal impacts—assuming a typical cold-and-flu season. It also expects high-single digit growth in organic operating profit. CFO Dawn Allen noted that a season slightly above or below normal could shift results by 50 to 100 basis points, or about 0.5 to 1 percentage point. Using Bloomberg FX rates, Haleon flagged a foreign exchange translation drag of roughly 2.8% on net revenue and 3.8% on adjusted operating profit for the full year.
Haleon’s portfolio includes Sensodyne toothpaste, Panadol painkillers, and Voltaren gel. Its publicly traded competitors span from UK consumer health giants like Reckitt to U.S.-listed Kenvue.
Traders face a key question: just how smooth will the run-up to earnings be? Even a defensive stock can swing sharply if estimates nudge slightly or if positioning turns crowded.
Still, the situation carries risks. A mild cold-and-flu season, a larger-than-anticipated currency headwind, or increased promotions in crucial categories might dent revenue growth and margins—even if demand remains steady elsewhere in the portfolio.
The shares have climbed over the past two sessions, so the coming days might hinge more on trading flows than on underlying fundamentals. Additional broker rating updates could stir up more activity.
